The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences
Gilead Sciences' headquarters in Foster City, California
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences about the impact of the COVID-19 epidemic, the company’s efforts to find an effective drug treatment for patients and the journey of remdesivir that began a decade ago as part of Gilead’s emerging viruses programme.
In May, remdesivir was granted an emergency use authorisation (EUA) for use in patients hospitalised with SARS-CoV-2, the virus which causes COVID-19. What were the trial results that led to this EUA?